Johnson & JohnsonNYSE: JNJ

In the Phase 3 GRAVITI study, more patients treated with subcutaneous TREMFYA® achieved clinical and endoscopic remission after 48 weeks compared to those given a placebo. If approved by the FDA, TREMFYA® could be the first IL-23 treatment to provide both subcutaneous and intravenous induction options for people with Crohn's disease. Johnson & Johnson shared these promising results at the American College of Gastroenterology (ACG) 2024 conference.

A groundbreaking Phase 3b study has shown that TREMFYA® (guselkumab) significantly improved skin conditions in adults with low body surface area psoriasis, particularly in sensitive areas like the scalp and face. Johnson & Johnson has also launched a collection of clinical images from the VISIBLE study to support better clinical decisions for individuals with moderate to severe plaque psoriasis across different skin tones. The findings from the SPECTREM study, which is the first large-scale clinical trial focusing on this specific group of patients, were shared at the 2024 Fall Clinical Dermatology Conference.

Recent five-year data supports the long-term safety and effectiveness of SPRAVATO® (esketamine) for patients who do not respond to two or more oral antidepressants, known as treatment-resistant depression. A total of 23 abstracts will showcase findings from the company's extensive research on major depressive disorder, as well as the challenges of anhedonia and insomnia. Additionally, a large real-world study emphasizes the connection between reducing relapse rates and improving survival in schizophrenia.

Johnson & Johnson (JNJ) has recently caught the attention of Zacks.com users. Therefore, it's important to look into what the future holds for this stock.

Johnson & Johnson's earnings for the third quarter of 2024 exceeded expectations, reaching $22.5 billion in revenue, thanks to strong sales from Darzalex, STELARA, and MedTech, even with some challenges. The company revised its full-year outlook, remaining positive despite issues like talc lawsuits and competition from STELARA generics, while continuing to generate strong cash flow and dividends. They anticipate that new growth in oncology and MedTech, along with strategic acquisitions, will help balance any potential drops in STELARA sales from generics.

Johnson & Johnson's JNJ stock price has started to rise again. A few years ago, the stock's growth slowed down because of the COVID-19 bubble bursting and the sale of Kenvue KVUE, but those challenges are now in the past, and the company is looking forward to future growth.

Johnson & Johnson shared encouraging news after reporting strong earnings for the third quarter of 2024. As a result, some analysts have increased their target price for the stock.

Johnson & Johnson (NYSE: JNJ) has just announced its Q3 results, showing that both revenue and earnings were higher than we expected. The company generated $22.5 billion in revenue and adjusted earnings of $2.42 per share, while we had predicted $22.2 billion and $2.20.

Johnson & Johnson's most recent financial review indicates that the company remains in very good shape.